Status:

COMPLETED

Memory Improvement With Docosahexaenoic Acid Study (MIDAS)

Lead Sponsor:

DSM Nutritional Products, Inc.

Conditions:

Age-Related Cognitive Decline

Age-Related Memory Disorders

Eligibility:

All Genders

55+ years

Phase:

NA

Brief Summary

The purpose of this study is to investigate the effect of docosahexaenoic acid (DHA, 22:6n-3) in improving cognitive functions in subjects with age-related cognitive decline. DHA is a long chain omega...

Eligibility Criteria

Inclusion

  • Males or females, aged 55 or greater.
  • Have a subjective memory complaint and have a Logical Memory subtest (of the Wechsler Memory Scale - III \[WMS-III\]) raw score one standard deviation or greater below the mean of a younger population.
  • Have the ability to understand the requirements of the study; be willing to provide written informed consent; and agree to abide by the study restrictions and return for the required assessments.
  • If taking non-prohibited medication, be on a stable drug regimen (in prior 3 months).

Exclusion

  • Have a screening Mini-Mental State Examination (MMSE) \< 26.
  • Consume greater than 200 mg/day DHA as assessed on a DHA Food Frequency Questionnaire in the prior 2 months to screening.
  • Use nutritional fish oil, flaxseed oil, omega-3 supplements, or huperzine in the prior 2 months to screening.
  • Use acetylcholinesterase inhibitors or memantine in the prior 2 months to screening.
  • Use major anti-psychotics or major anti-depressants.
  • Use lipase inhibitors such as Xenical® (orlistat).
  • History of major medical conditions including ischemic stroke, head trauma with loss of consciousness, epilepsy, psychosis, vascular dementia, depression (Geriatric Depression \[15-item\] \> 5), myocardial infarction (within 1 year), uncontrolled diabetes, or blindness.
  • History of major surgery within the past 6 months.
  • Current use or history of drug and/or alcohol abuse within 5 years.
  • Administration of any investigational product within the past 30 days.
  • Inability to swallow capsules.

Key Trial Info

Start Date :

December 1 2005

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2008

Estimated Enrollment :

485 Patients enrolled

Trial Details

Trial ID

NCT00278135

Start Date

December 1 2005

End Date

December 1 2008

Last Update

May 19 2014

Active Locations (14)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (14 locations)

1

Pivotal Research Center

Mesa, Arizona, United States, 85210

2

Pacific Research Network

San Diego, California, United States, 92103

3

Pacific Research Network

Vista, California, United States, 92083

4

Radiant Research Denver

Denver, Colorado, United States, 80212

Memory Improvement With Docosahexaenoic Acid Study (MIDAS) | DecenTrialz